| Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates |
Century Therapeutics, Inc. (IPSC) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to loss of $0.45 per share a year ago. |
zacks.com |
2025-05-16 01:16:05 |
Czytaj oryginał (ang.) |
| Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update |
PHILADELPHIA, May 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results and business highlights for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-15 20:01:00 |
Czytaj oryginał (ang.) |
| Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release |
Century Therapeutics (IPSC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:07:14 |
Czytaj oryginał (ang.) |
| Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting |
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. The presentations will highlight data supporting the company's emerging preclinical cell therapy pipeline and investigational programs for autoimmune diseases and cancer. |
globenewswire.com |
2025-04-28 20:30:00 |
Czytaj oryginał (ang.) |
| Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock? |
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-03-25 15:01:06 |
Czytaj oryginał (ang.) |
| Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates |
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.49 per share a year ago. |
zacks.com |
2025-03-19 20:15:22 |
Czytaj oryginał (ang.) |
| Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update |
PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results and business highlights for the full year 2024. |
globenewswire.com |
2025-03-19 18:01:00 |
Czytaj oryginał (ang.) |
| Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference |
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024: |
globenewswire.com |
2024-11-26 09:00:00 |
Czytaj oryginał (ang.) |
| What Makes Century Therapeutics (IPSC) a New Buy Stock |
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-11-08 15:01:14 |
Czytaj oryginał (ang.) |
| Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates |
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.55 per share a year ago. |
zacks.com |
2024-11-05 13:16:52 |
Czytaj oryginał (ang.) |
| Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates |
– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy – |
globenewswire.com |
2024-11-05 11:05:00 |
Czytaj oryginał (ang.) |
| Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference |
PHILADELPHIA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer, will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 9:30am ET. |
globenewswire.com |
2024-11-04 09:00:00 |
Czytaj oryginał (ang.) |
| Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer |
- Morgan Conn, Ph.D., seasoned biotech executive with expertise in financing, business development, and corporate strategy, appointed as Chief Financial Officer - |
globenewswire.com |
2024-09-26 11:00:00 |
Czytaj oryginał (ang.) |
| Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates |
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.56 per share a year ago. |
zacks.com |
2024-08-08 13:50:23 |
Czytaj oryginał (ang.) |
| Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates |
– Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis patients – |
globenewswire.com |
2024-08-08 11:30:00 |
Czytaj oryginał (ang.) |
| Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade |
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-07-09 17:01:31 |
Czytaj oryginał (ang.) |
| Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101 |
Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma market is expected to surge to $11 billion by 2029. Initiation of phase 1 CALiPSO-1 study, using CNTY-101 for patients with systemic lupus erythematosus, is expected in the 1st half of 2024; Data from this study is to be released 2nd half of 2024. |
seekingalpha.com |
2024-06-20 15:07:05 |
Czytaj oryginał (ang.) |
| Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting |
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting |
globenewswire.com |
2024-06-03 11:00:00 |
Czytaj oryginał (ang.) |
| Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates |
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.53 per share a year ago. |
zacks.com |
2024-05-09 13:40:25 |
Czytaj oryginał (ang.) |
| Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates |
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) |
globenewswire.com |
2024-05-09 11:30:00 |
Czytaj oryginał (ang.) |
| Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit |
PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows: |
globenewswire.com |
2024-04-23 11:00:00 |
Czytaj oryginał (ang.) |
| Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics |
Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile |
globenewswire.com |
2024-04-11 11:00:00 |
Czytaj oryginał (ang.) |
| Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting |
PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company's iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024. The posters highlight the Company's end-to-end capabilities in iPSC reprogramming and differentiation, gene editing, synthetic biology, protein engineering and computational biology. |
globenewswire.com |
2024-04-08 20:05:00 |
Czytaj oryginał (ang.) |
| Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference |
PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET. |
globenewswire.com |
2024-03-19 09:00:00 |
Czytaj oryginał (ang.) |
| Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates |
- Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™ may support a multi-dosing regimen without the need for continued lymphodepletion - |
globenewswire.com |
2024-03-14 09:30:00 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4% |
The average of price targets set by Wall Street analysts indicates a potential upside of 193.4% in Century Therapeutics, Inc. (IPSC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-03-07 12:56:05 |
Czytaj oryginał (ang.) |
| Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting |
Posters will highlight Century's end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and computational biology Posters will highlight Century's end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and computational biology |
globenewswire.com |
2024-03-05 20:03:00 |
Czytaj oryginał (ang.) |